53 Comparison of Surgical Complications With Direct-to-Implant vs Tissue Expander Reconstruction After Wise Pattern Skin-Sparing Mastectomy

Publication
Article
Miami Breast Cancer Conference® Abstracts Supplement42nd Annual Miami Breast Cancer Conference® - Abstracts
Volume 39
Issue 4
Pages: 48-49

53 Comparison of Surgical Complications With Direct-to-Implant vs Tissue Expander Reconstruction After Wise Pattern Skin-Sparing Mastectomy

53 Comparison of Surgical Complications With Direct-to-Implant vs Tissue Expander Reconstruction After Wise Pattern Skin-Sparing Mastectomy

Background

Wise Pattern Mastectomy is a common incision utilized in patients with large, ptotic breasts undergoing skin-sparing mastectomy and immediate breast reconstruction (IBR). This incision pattern is associated with an increased risk of delayed wound healing and skin necrosis, which may be further influenced by the type of IBR performed. We compared surgical complications in patients undergoing IBR with Direct-to-Implant (DTI) vs Tissue Expander (TE) after Wise Pattern Skin-Sparing Mastectomy (WSSM).

Materials and Methods

Patients who underwent WSSM and IBR from 2019 to 2023 were selected. Patient characteristics, clinical features, and surgical complications were compared between patients who underwent DTI vs TE IBR. Multivariable logistic regression analysis was performed to identify factors associated with major complications (surgical site infection [SSI], skin necrosis requiring reoperation, and reconstruction loss) and any 30-day complication controlling for patient age, race, ethnicity, body mass index (BMI), presence of diabetes, tobacco use, neoadjuvant chemotherapy, reason for mastectomy, axillary surgery, mastectomy weight, and type of reconstruction.

Status

A total of 144 patients who underwent 217 mastectomies were evaluated: 73 bilateral (51%) and 71 unilateral (49%); 117 DTI (54%) and 100 TE (46%). (Table) Most patients were ≥ 50 years old (64%), White (83%), Hispanic (64%), and had a BMI < 30 kg/m2 (58%). Neoadjuvant chemotherapy was utilized in 35% of patients. The reason for mastectomy was cancer in 64%, and axillary surgery was performed in 66% of cases. The mastectomy weight was ≥ 1000 grams in 41% of cases. Major complications occurred in 21% of cases: SSI in 12% (DTI 15% vs TE 9%), skin necrosis requiring reoperation in 11% (DTI 12% vs TE 10%), and reconstruction loss in 13% (DTI 15% vs TE 10%). SSI and skin necrosis requiring reoperation were associated with reconstruction loss (SSI, P ≤.001; skin necrosis, P ≤.001). Multivariable analysis showed that breast weight ≥ 1000 grams was associated with major complications (OR, 2.82; 95% CI 1.27-6.26; P = .011) and Hispanic ethnicity, current smoking, and DTI reconstruction were associated with any 30-day complication (Hispanic ethnicity: OR, 3.33; 95% CI 1.62-6.87; P = .001; current smoking: OR, 5.57; 95% CI 1.05-29.02; P = .044; DTI, OR, 2.40; 95% CI 1.31-4.40; P = .005).

Table. Patient Characteristics, Clinical Features, and Surgical Outcomes

Table. Patient Characteristics, Clinical Features, and Surgical Outcomes

Articles in this issue

3 Intraoperative Radiotherapy: Alive and Well in the Bronx
3 Intraoperative Radiotherapy: Alive and Well in the Bronx
4 Evaluating AI-Driven Responses in Breast Reconstruction: A Comparative Study of Response Formats
4 Evaluating AI-Driven Responses in Breast Reconstruction: A Comparative Study of Response Formats
5 Correlation Between Visual Impairment and Breast Cancer: A Cross-Sectional Study Based on the National Health Interview Surveys
5 Correlation Between Visual Impairment and Breast Cancer: A Cross-Sectional Study Based on the National Health Interview Surveys
6 Peer Support Programming Among Women At-Risk for Surviving Breast Cancer: Facilitators and Barriers to Community-Based Patient Navigation and the Role of Quality of Life
6 Peer Support Programming Among Women At-Risk for Surviving Breast Cancer: Facilitators and Barriers to Community-Based Patient Navigation and the Role of Quality of Life
7 Metaplastic Breast Cancer: A Retrospective Chart Review of Clinical Features
7 Metaplastic Breast Cancer: A Retrospective Chart Review of Clinical Features
8 A Case Series Exploring Characteristics and Outcomes of Metachronous Primary Breast and Lung Cancer in a Diverse Cohort
8 A Case Series Exploring Characteristics and Outcomes of Metachronous Primary Breast and Lung Cancer in a Diverse Cohort
9 Body Mass Index, Cancer Risk Behaviors, and Readiness for Dietary Change Among Women Surviving With Breast Cancer
9 Body Mass Index, Cancer Risk Behaviors, and Readiness for Dietary Change Among Women Surviving With Breast Cancer
10 AI as a Bridge: Can ChatGPT Help Patients Understand Their Breast Radiology Reports?
10 AI as a Bridge: Can ChatGPT Help Patients Understand Their Breast Radiology Reports?
12 Gut Microbiome Composition and Pathological Complete Response After Chemotherapy in Breast Cancer: Insights From a Pilot Study
12 Gut Microbiome Composition and Pathological Complete Response After Chemotherapy in Breast Cancer: Insights From a Pilot Study
13 Preliminary Analysis of Change During Treatment of Financial Toxicity and Quality of Life in Breast Cancer Patients
13 Preliminary Analysis of Change During Treatment of Financial Toxicity and Quality of Life in Breast Cancer Patients
15 Utilizing Circulating Tumor Cells to Guide HER2-Directed Therapy in IHC/FISH-Negative HER2+ Metastatic Breast Cancer
15 Utilizing Circulating Tumor Cells to Guide HER2-Directed Therapy in IHC/FISH-Negative HER2+ Metastatic Breast Cancer
16 A Miami Hospital’s Infrastructure to Help Decrease Late-Stage Breast Cancer Diagnosis and Improve Health Equity
16 A Miami Hospital’s Infrastructure to Help Decrease Late-Stage Breast Cancer Diagnosis and Improve Health Equity
17 Salmonella and the Breast: A Literature Review of Salmonella-Induced Breast Abscesses
17 Salmonella and the Breast: A Literature Review of Salmonella-Induced Breast Abscesses
18 Tolerability of First-Line Treatment With Ribociclib for Metastatic Breast Cancer Using 2 Large US Data Sources
18 Tolerability of First-Line Treatment With Ribociclib for Metastatic Breast Cancer Using 2 Large US Data Sources
20 Impact of Ribociclib Dose Reduction on Efficacy in Patients With Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Early Breast
20 Impact of Ribociclib Dose Reduction on Efficacy in Patients With Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Early Breast

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
Patients with node-negative disease who are older and have comorbidities may not be suitable to receive CDK4/6 inhibitors.
An observed carryover effect with CDK4/6 inhibitors may reduce the risk of recurrence years after a patient stops treatment.
Those being treated for peritoneal carcinomatosis may not have to experience the complication rates or prolonged recovery associated with surgical options.
For patients with peritoneal carcinomatosis, integrating PIPAC into a treatment regimen does not interrupt their systemic therapy.
According to Benjamin J. Golas, MD, PIPAC could be used as a bridging therapy before surgical debulking or between subsequent large surgical operations.
Breast oncologist Jade E. Jones, MD, says she tries to send patients with BRCA-mutant HR-positive TNBC to clinical trials that use PARP inhibitors.
Following progression on a CDK4/6 inhibitor, ascertaining the endocrine sensitivity of HR-positive/HER2-negative disease may inform sequential treatment.
T-DXd improved progression-free survival over standard chemotherapy among patients with HR-positive/triple-negative breast cancer in DESTINY-Breast04.